
Latest News
Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario
February 20, 2025
Apo-Teriparatide Injection ™ is a generic alternative to Forteo®.
Osteoporosis pharmacologic therapies are classified as antiresorptive therapy, which inhibits osteoclastic activity, and anabolic therapy, which stimulates new bone formation. Apo-Teriparatide is an anabolic therapy.
To view more information about provincial and territorial drug coverage visit https://osteoporosis.ca/provincial-territorial-drug-coverage/
OC MAKES THE NEWS – RECENT ITEMS
Osteoporosis Canada Becomes HealthPartners Member
May 16, 2025
Latest News Osteoporosis Canada Becomes HealthPartners Member May 16, 2025 In March 2025 it was announced that Osteoporosis Canada was one of three new charities to join the membership of […]
Dr. Lora Giangregorio Named Canada Research Chair
March 19, 2025
Latest News Dr. Lora Giangregorio Named Canada Research Chair March 19, 2025 The University of Waterloo, Kinesiology and Health Sciences Professor Lora Giangregorio has been awarded a Tier 1 Canada […]
Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario
February 20, 2025
Latest News Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario February 20, 2025 Apo-Teriparatide Injection ™ is a generic alternative to Forteo®. Osteoporosis pharmacologic therapies are classified […]